PRESENTATION
Q4 2023 — Presentation
Q4 2023PDF · 33 pages670 KB
Danaher Corporation Fourth Quarter 2023 Earnings Release January 30, 2024 -- 1 of 33 -- 2 Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, potential future, adverse impacts on our business, results of operations and financial condition related to the COVID-19 pandemic , the impact of our debt obligations on our operations and liquidity, deterioration of or instability in the economy, the markets we serve and the financial markets, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments and successfully complete divestitures and other dispositions, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions (including the acquisition of Abcam plc), contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government with respect to our production capacity in times of national emergency or with respect to intellectual property/production capacity developed using government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to fluctuations in the cost and availability of the supplies we use (including commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, the impact of deregulation on demand for our products and services, the impact of climate change, legal or regulatory measures to address climate change and our ability to address stakeholder expectations relating to climate change, labor matters and our ability to recruit, retain and motivate talented employees representing diverse backgrounds, experiences and skill sets, non-U.S. economic, political, legal, compliance, social and business factors (including the impact of military conflicts), disruptions relating to man-made and natural disasters, pension plan and healthcare costs, inflation and the impact of our By-law exclusive forum provisions. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2022 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the third quarter of 2023. These forward-looking statements speak only as of the date of this presentation (January 30, 2024) and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise. With respect to the non-GAAP financial measures referenced in the following presentation, definitions and the accompanying information required by SEC Regulation G can be found in this presentation or in the “Investors” section of Danaher’s web site, www.danaher.com, under the heading “Financial Reports” and subheading “Quarterly Earnings.” In addition, in addressing various financial metrics the presentation describes certain of the more significant factors that impacted year-over-year performance. For additional factors that impacted year-over-year performance, please refer to our earnings release and the other related presentation materials supplementing today’s call, all of which are available in the “Investors” section of Danaher’s web site under the heading “Financial Reports” and subheading “Quarterly Earnings,” as well as our Annual Report on Form 10-K for the year-ended December 31, 2023 when it becomes available. All references in this presentation (1) to financial metrics relate only to the continuing operations of Danaher’s business, unless otherwise noted; and (2) to “growth” or other period-to-period changes refer to year-over-year comparisons unless otherwise indicated. We may also describe certain products and devices which have applications submitted and pending for certain regulatory approvals. -- 2 of 33 -- 3 Performance Summary: Revenue Throughout this presentation, with respect to revenue performance, for the definitions of "Acquisitions," “Core,” and “FX,” please refer to the accompanying information required by Regulation G, located at the end of this presentation and on the "Investors" section of Danaher's website. $26,643 $23,890 FY 2022 FY 2023 FY Revenue -10.5% Core -10.0% Acquisitions +0.5% FX -1.0% ($ millions) $7,134 $6,405 Q4 2022 Q4 2023 Q4 Revenue -10.0% Core -11.5% Acquisitions +0.5% FX +1.0% ($ millions) -- 3 of 33 -- 4 Performance Summary: Operating Profit Margin Throughout this presentation when referred to in connection with operating profit margins, “Acquisitions” refers to the impact of businesses owned for less than one year or disposed of during such period and not treated as discontinued operations, “Other” refers to the impact of 2023 transaction costs deemed significant, settlement of pre-acquisition share-based payment awards and fair value adjustments to inventory, in each case related to the acquisition of Abcam plc, and impairment and other charges incurred in 2023 and 2022 net of a 2023 gain from the resolution of a litigation contingency; for further description of these items, please refer to the accompanying information required by Regulation G, located at the end of this presentation and on the "Investors" section of Danaher's website. 28.3% 21.8% FY 2022 FY 2023 FY Operating Profit Margin -650 BPS Core -575 bps Acquisitions -20 bps Other -55 bps 28.0% 20.9% Q4 2022 Q4 2023 Q4 Operating Profit Margin -710 BPS Core -495 bps Acquisitions -25 bps Other -190 bps -- 4 of 33 -- 5 Performance Summary: Adjusted Diluted Net EPS Throughout this presentation, with respect to revenue performance, for the definitions of "Acquisitions," “Core,” and “FX,” please refer to the accompanying information required by Regulation G, located at the end of this presentation and on the "Investors" section of Danaher's website. $9.71 $7.58 FY 2022 FY 2023 FY Adjusted Diluted Net Earnings Per Common Share -22.0% $2.54 $2.09 Q4 2022 Q4 2023 Q4 Adjusted Diluted Net Earnings Per Common Share -17.5% -- 5 of 33 -- Performance Summary: Free Cash Flow Please refer to the accompanying information required by Regulation G, located at the end of this presentation and on the "Investors" section of Danaher's website for a description of Free Cash Flow. $6,504 $5,119 FY 2022 FY 2023 FY Free Cash Flow Performance -21.5% $1,879 $1,163 Q4 2022 Q4 2023 Q4 Free Cash Flow Performance -38.0% ($ millions) 6 ($ millions) -- 6 of 33 -- Fourth Quarter 2023: Biotechnology $2,223 $1,759 Q4 2022 Q4 2023 Revenue -21.0% Core -22.5% FX +1.5% 31.2% 23.6% Q4 2022 Q4 2023 Operating Profit Margin -760 BPS Core -690 bps Other -70 bps ($ millions) 7 -- 7 of 33 -- Fourth Quarter 2023: Life Sciences $1,946 $1,930 Q4 2022 Q4 2023 Revenue -1.0% Core -4.0% Acquisitions +2.5% FX +0.5% 20.1% 12.2% Q4 2022 Q4 2023 Operating Profit Margin -790 BPS Core -280 bps Acquisitions -75 bps Other -435 bps ($ millions) 8 -- 8 of 33 -- Fourth Quarter 2023: Diagnostics $2,965 $2,716 Q4 2022 Q4 2023 Revenue -8.5% Core -8.5% 33.4% 28.2% Q4 2022 Q4 2023 Operating Profit Margin -520 BPS Core -430 bps Other -90 bps ($ millions) 9 -- 9 of 33 -- Guidance 10 -- 10 of 33 -- Q&A 11 -- 11 of 33 -- -- 12 of 33 -- DANAHER CORPORATION RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES AND SUPPLEMENTAL FORWARD-LOOKING INFORMATION THREE-MONTH PERIODS AND YEARS ENDED DECEMBER 31, 2023 AND DECEMBER 31, 2022 -- 13 of 33 -- TABLE OF CONTENTS Page 1 Sales (Decline) Growth by Segment, Core Sales (Decline) Growth by Segment and Base Business Core Sales (Decline) Growth by Segment 2 Forecasted Core Sales (Decline) Growth and Adjusted Operating Profit Margin 3 Segment Sales, Operating Profit and Adjusted Operating Profit 4 Net Earnings From Continuing Operations, Operating Profit, Adjusted EBITDA, Net Earnings from Continuing Operations Margin, Operating Profit Margin and Adjusted EBITDA Margin 8 Other Non-GAAP Adjusted P&L Measures 14 Average and Adjusted Average Common Stock and Common Equivalent Diluted Shares Outstanding 15 Year-Over-Year Core Operating Margin Changes from Continuing Operations 16 Cash Flow from Continuing Operations, Free Cash Flow from Continuing Operations, Operating Cash Flow from Continuing Operations to Net Earnings from Continuing Operations Ratio and Free Cash Flow from Continuing Operations to Net Earnings from Continuing Operations Conversion Ratio 17 Statement Regarding Non-GAAP Measures FORWARD-LOOKING STATEMENTS DISCLOSURE Statements in this document that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward- looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, potential future, adverse impacts on our business, results of operations and financial condition related to the COVID-19 pandemic, the impact of our debt obligations on our operations and liquidity, deterioration of or instability in the economy, the markets we serve and the financial markets, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments and successfully complete divestitures and other dispositions, our ability to integrate the businesses we acquire (including the acquisition of Abcam plc) and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government with respect to our production capacity in times of national emergency or with respect to intellectual property/production capacity developed using government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to fluctuations in the cost and availability of the supplies we use (including commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, the impact of deregulation on demand for our products and services, the impact of climate change, legal or regulatory measures to address climate change and our ability to address stakeholder expectations relating to climate change, labor matters and our ability to recruit, retain and motivate talented employees representing diverse backgrounds, experiences and skill sets, non-U.S. economic, political, legal, compliance, social and business factors (including the impact of military conflicts), disruptions relating to man-made and natural disasters, pension plan and healthcare costs, inflation and the impact of our By-law exclusive forum provisions. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2022 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the third quarter of 2023. These forward-looking statements speak only as of the date of this document (January 29, 2024) and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise. -- 14 of 33 -- % Change Three-Month Period Ended December 31, 2023 vs. Comparable 2022 Period Segments Total Company Biotechnology Life Sciences Diagnostics Total sales decline (GAAP) (10.0) % (21.0) % (1.0) % (8.5) % Impact of: Acquisitions/divestitures (0.5) % — % (2.5) % — % Currency exchange rates (1.0) % (1.5) % (0.5) % — % Core sales decline (non-GAAP) (11.5) % (22.5) % (4.0) % (8.5) % Impact of COVID-19 related testing, vaccines and therapeutics 7.0 % +Mid-single digit +Up slightly +High-teens Base business core sales (decline) growth (non-GAAP) (4.5) % -High-teens -Low-single digit +High-single digit % Change Year Ended December 31, 2023 vs. Comparable 2022 Period Segments Total Company Biotechnology Life Sciences Diagnostics Total sales (decline) growth (GAAP) (10.5) % (18.0) % 1.5 % (11.5) % Impact of: Acquisitions/divestitures (0.5) % — % (1.5) % — % Currency exchange rates 1.0 % — % 1.0 % 1.0 % Core sales (decline) growth (non-GAAP) (10.0) % (18.0) % 1.0 % (10.5) % Impact of COVID-19 related testing, vaccines and therapeutics 9.5 % +High-single digit +Low-single digit +High-teens Base business core sales (decline) growth (non-GAAP) (0.5) % -Low-double digit +Low-single digit +High-single digit Note: We expect overall demand for the Company’s COVID-19 related products to continue moderating as the pandemic has evolved toward endemic status. We believe certain demand for the Company’s products that support COVID-19 related vaccines and therapeutics and COVID-19 testing (which includes solutions that test for COVID-19 and other respiratory illnesses simultaneously) will continue, though that demand will likely be uncertain and will vary from period to period. At the beginning of 2022, the Company believed that on a relative basis, the level of ongoing demand for products supporting COVID-19 testing would be subject to more fluctuations in demand than the level of demand for products supporting COVID-19 related vaccines and therapeutics, due in part to expected COVID-19 case levels, vaccination rates and use of therapies. However, as a result of lower vaccination rates and the spread of less severe variants of the virus, 2022 demand for the Company’s products supporting COVID-19 related vaccines and therapeutics fluctuated and declined more than anticipated at the beginning of the year. Therefore, beginning with the first quarter of 2023, we have revised the definition of “base business core sales growth” on a basis that not only excludes revenues related to COVID-19 testing but also excludes revenues from products that support COVID-19 related vaccines and therapeutics. We believe this adjusted definition of “base business core sales growth” provides more useful information to investors by facilitating period-to-period comparisons of our financial performance and identifying underlying growth trends in the Company’s business that otherwise may be obscured by fluctuations in demand for COVID-19 related products. DANAHER CORPORATION Sales (Decline) Growth by Segment, Core Sales (Decline) Growth by Segment and Base Business Core Sales (Decline) Growth by Segment 1 -- 15 of 33 -- The Company provides forecasted sales only on a non-GAAP basis because of the difficulty in estimating the other components of GAAP revenue, such as currency translation, acquisitions and divested product lines. Beginning with the first quarter of 2024 the Company will continue to provide guidance for core revenue growth, but will no longer provide guidance for, or report base business core revenue as the pandemic has transitioned to an endemic state. Additionally, we do not reconcile forecasted adjusted operating profit margin (or components thereof) to the comparable GAAP measures because of the difficulty in estimating the other components (in addition to items identified in the prior sentence) such as investment gains and losses, impairments and separation costs, which would be reflected in any forecasted GAAP operating profit. % Change Three-Month Period Ending March 29, 2024 vs. Comparable 2023 Period % Change Year Ending December 31, 2024 vs. Comparable 2023 Period Core sales decline (non-GAAP) -High-single digit -Low-single digit Three-Month Period Ending March 29, 2024 Adjusted operating profit margin (non-GAAP) ~28.0 % Year Ending December 31, 2024 Year-over-year change in adjusted operating profit margin (non-GAAP) ~+0.5% DANAHER CORPORATION Forecasted Core Sales Decline and Adjusted Operating Profit Margin 2 -- 16 of 33 -- Sales (GAAP) Biotechnology $ 1,759 $ 2,223 $ 7,172 $ 8,758 Life Sciences 1,930 1,946 7,141 7,036 Diagnostics 2,716 2,965 9,577 10,849 Total Company $ 6,405 $ 7,134 $ 23,890 $ 26,643 Operating Profit (GAAP) Biotechnology $ 416 $ 693 $ 1,909 $ 3,008 Life Sciences 235 392 1,209 1,414 Diagnostics 766 989 2,406 3,436 Other (80) (77) (322) (322) Total Company $ 1,337 $ 1,997 $ 5,202 $ 7,536 Amortization of Intangible Assets (GAAP) Biotechnology $ 215 $ 196 $ 864 $ 812 Life Sciences 116 104 429 419 Diagnostics 49 52 198 203 Total Company $ 380 $ 352 $ 1,491 $ 1,434 Other Operating Profit Adjustments 1 Biotechnology $ 12 $ — $ 54 $ 14 Life Sciences 85 — 85 24 Diagnostics 23 — 23 3 Other — — — 1 Total Company $ 120 $ — $ 162 $ 42 Adjusted Operating Profit (non-GAAP) 2 Biotechnology $ 643 $ 889 $ 2,827 $ 3,834 Life Sciences 436 496 1,723 1,857 Diagnostics 838 1,041 2,627 3,642 Other (80) (77) (322) (321) Total Company $ 1,837 $ 2,349 $ 6,855 $ 9,012 Three-Month Period Ended Year Ended December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 1 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments. 2 Adjusted Operating Profit (non-GAAP) is defined as operating profit (GAAP) plus amortization of intangible assets (GAAP) plus (minus) Other Operating Profit Adjustments (as defined). DANAHER CORPORATION Segment Sales, Operating Profit and Adjusted Operating Profit ($ in millions) 3 -- 17 of 33 -- Three-Month Period Ended December 31, 2023 Biotechnology Life Sciences Diagnostics Other Total Company Net Earnings from Continuing Operations (GAAP) $ 1,121 Interest, Net (32) Other Nonoperating (Income) Expense 137 Income Taxes 111 Operating Profit (GAAP) $ 416 $ 235 $ 766 $ (80) $ 1,337 Other Operating Profit Adjustments 1 12 85 23 — 120 Depreciation 43 37 97 1 178 Amortization of Intangible Assets 215 116 49 — 380 Adjusted EBITDA (Non-GAAP) $ 686 $ 473 $ 935 $ (79) $ 2,015 Interest, Net 32 Other Nonoperating Income (Expense) (137) Income Taxes (111) Other Operating Profit Adjustments 1 (120) Depreciation (178) Amortization of Intangible Assets (380) Net Earnings from Continuing Operations (GAAP) $ 1,121 Sales (GAAP) $ 1,759 $ 1,930 $ 2,716 $ 6,405 Net Earnings from Continuing Operations Margin (GAAP) 17.5 % Operating Profit Margin (GAAP) 23.6 % 12.2 % 28.2 % 20.9 % Adjusted EBITDA Margin (Non-GAAP) 3 39.0 % 24.5 % 34.4 % 31.5 % 1 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments. 3 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by Sales (GAAP). DANAHER CORPORATION Net Earnings From Continuing Operations, Operating Profit, Adjusted EBITDA, Net Earnings From Continuing Operations Margin, Operating Profit Margin and Adjusted EBITDA Margin ($ in millions) 4 -- 18 of 33 -- Three-Month Period Ended December 31, 2022 Biotechnology Life Sciences Diagnostics Other Total Company Net Earnings from Continuing Operations (GAAP) $ 2,012 Interest, Net 33 Other Nonoperating (Income) Expense 69 Income Taxes (117) Operating Profit (GAAP) $ 693 $ 392 $ 989 $ (77) $ 1,997 Other Operating Profit Adjustments 1 — — — — — Depreciation 63 28 97 4 192 Amortization of Intangible Assets 196 104 52 — 352 Adjusted EBITDA (Non-GAAP) $ 952 $ 524 $ 1,138 $ (73) $ 2,541 Interest, Net (33) Other Nonoperating Income (Expense) (69) Income Taxes 117 Other Operating Profit Adjustments 1 — Depreciation (192) Amortization of Intangible Assets (352) Net Earnings from Continuing Operations (GAAP) $ 2,012 Sales (GAAP) $ 2,223 $ 1,946 $ 2,965 $ 7,134 Net Earnings from Continuing Operations Margin (GAAP) 28.2 % Operating Profit Margin (GAAP) 31.2 % 20.1 % 33.4 % 28.0 % Adjusted EBITDA Margin (Non-GAAP) 3 42.8 % 26.9 % 38.4 % 35.6 % 1 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments. 3 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by Sales (GAAP). DANAHER CORPORATION Net Earnings From Continuing Operations, Operating Profit, Adjusted EBITDA, Net Earnings From Continuing Operations Margin, Operating Profit Margin and Adjusted EBITDA Margin ($ in millions) 5 -- 19 of 33 -- Year Ended December 31, 2023 Biotechnology Life Sciences Diagnostics Other Total Company Net Earnings from Continuing Operations (GAAP) $ 4,221 Interest, Net (17) Other Nonoperating (Income) Expense 175 Income Taxes 823 Operating Profit (GAAP) $ 1,909 $ 1,209 $ 2,406 $ (322) $ 5,202 Other Operating Profit Adjustments 1 54 85 23 — 162 Depreciation 162 129 379 5 675 Amortization of Intangible Assets 864 429 198 — 1,491 Adjusted EBITDA (Non-GAAP) $ 2,989 $ 1,852 $ 3,006 $ (317) $ 7,530 Interest, Net 17 Other Nonoperating Income (Expense) (175) Income Taxes (823) Other Operating Profit Adjustments 1 (162) Depreciation (675) Amortization of Intangible Assets (1,491) Net Earnings from Continuing Operations (GAAP) $ 4,221 Sales (GAAP) $ 7,172 $ 7,141 $ 9,577 $ 23,890 Net Earnings from Continuing Operations Margin (GAAP) 17.7 % Operating Profit Margin (GAAP) 26.6 % 16.9 % 25.1 % 21.8 % Adjusted EBITDA Margin (Non-GAAP) 3 41.7 % 25.9 % 31.4 % 31.5 % 1 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments. 3 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by Sales (GAAP). DANAHER CORPORATION Net Earnings From Continuing Operations, Operating Profit, Adjusted EBITDA, Net Earnings From Continuing Operations Margin, Operating Profit Margin and Adjusted EBITDA Margin ($ in millions) 6 -- 20 of 33 -- Year Ended December 31, 2022 Biotechnology Life Sciences Diagnostics Other Total Company Net Earnings from Continuing Operations (GAAP) $ 6,328 Interest, Net 163 Other Nonoperating (Income) Expense 227 Income Taxes 818 Operating Profit (GAAP) $ 3,008 $ 1,414 $ 3,436 $ (322) $ 7,536 Other Operating Profit Adjustments 1 14 24 3 1 42 Depreciation 190 112 387 9 698 Amortization of Intangible Assets 812 419 203 — 1,434 Adjusted EBITDA (Non-GAAP) $ 4,024 $ 1,969 $ 4,029 $ (312) $ 9,710 Interest, Net (163) Other Nonoperating Income (Expense) (227) Income Taxes (818) Other Operating Profit Adjustments 1 (42) Depreciation (698) Amortization of Intangible Assets (1,434) Net Earnings from Continuing Operations (GAAP) $ 6,328 Sales (GAAP) $ 8,758 $ 7,036 $ 10,849 $ 26,643 Net Earnings from Continuing Operations Margin (GAAP) 23.8 % Operating Profit Margin (GAAP) 34.3 % 20.1 % 31.7 % 28.3 % Adjusted EBITDA Margin (Non-GAAP) 3 45.9 % 28.0 % 37.1 % 36.4 % 1 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments. 3 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by Sales (GAAP). DANAHER CORPORATION Net Earnings From Continuing Operations, Operating Profit, Adjusted EBITDA, Net Earnings From Continuing Operations Margin, Operating Profit Margin and Adjusted EBITDA Margin ($ in millions) 7 -- 21 of 33 -- Three-Month Period Ended December 31, 2023 Sales Cost of sales Gross profit margin Operating profit Operating profit margin Earnings from continuing operations before income taxes Income taxes Net earnings from continuing operations for calculation of diluted earnings per common share Diluted net earnings per common share from continuing operations 4 Reported (GAAP) $ 6,405 $ (2,626) 59.0 % $ 1,337 20.9 % $ 1,232 $ (111) $ 1,121 J $ 1.50 Amortization of acquisition-related intangible assets A — — — 380 5.9 380 380 0.51 Fair value net (gains) losses on investments B — — — — — 139 139 0.19 Impairments and other charges C — — — 35 0.5 35 35 0.05 Acquisition-related items D — 8 0.1 95 1.5 95 95 0.13 Litigation gains E — — — (10) (0.2) (10) (10) (0.01) Tax effect of the above adjustments G (131) (131) (0.18) Discrete tax adjustments H (71) (71) (0.10) Rounding — — — — 0.1 — — — — Adjusted (Non-GAAP) $ 6,405 $ (2,618) 59.1 % $ 1,837 28.7 % $ 1,871 $ (313) $ 1,558 $ 2.09 Three-Month Period Ended December 31, 2023 Sales Selling, general and administrative expenses Selling, general and administrative expenses as a % of sales Research and development expenses Research and development expenses as a % of sales Nonoperating income (expense), net (excluding interest) Interest income (expense), net Reported (GAAP) $ 6,405 $ (2,035) (31.8) % $ (407) (6.4) % $ (137) $ 32 Amortization of acquisition-related intangible assets A — 380 5.9 — — — — Fair value net (gains) losses on investments B — — — — — 139 — Impairments and other charges C — 35 0.5 — — — — Acquisition-related items D — 87 1.4 — — — — Litigation gains E — (10) (0.2) — — — — Rounding — — 0.1 — — — — Adjusted (Non-GAAP) $ 6,405 $ (1,543) (24.1) % $ (407) (6.4) % $ 2 $ 32 4 Net earnings per diluted common share amounts for the relevant three-month periods may not add to the year-to-date amounts due to rounding. DANAHER CORPORATION Other Non-GAAP Adjusted P&L Measures ($ in millions, except per share data) 8 -- 22 of 33 -- Three-Month Period Ended December 31, 2022 Sales Cost of sales Gross profit margin Operating profit Operating profit margin Earnings from continuing operations before income taxes Income taxes Net earnings from continuing operations for calculation of diluted earnings per common share Diluted net earnings per common share from continuing operations 5 Reported (GAAP) $ 7,134 $ (2,908) 59.2 % $ 1,997 28.0 % $ 1,895 $ 117 $ 2,012 J $ 2.70 Amortization of acquisition-related intangible assets A — — — 352 4.9 352 352 0.47 Fair value net (gains) losses on investments B — — — — — 85 85 0.11 Tax effect of the above adjustments G (94) (94) (0.13) Discrete tax adjustments H (459) (459) (0.62) Rounding — — — — — — — 0.01 Adjusted (Non-GAAP) $ 7,134 $ (2,908) 59.2 % $ 2,349 32.9 % $ 2,332 $ (436) $ 1,896 $ 2.54 Three-Month Period Ended December 31, 2022 Sales Selling, general and administrative expenses Selling, general and administrative expenses as a % of sales Research and development expenses Research and development expenses as a % of sales Nonoperating income (expense), net (excluding interest) Interest income (expense), net Reported (GAAP) $ 7,134 $ (1,829) (25.6) % $ (400) (5.6) % $ (69) $ (33) Amortization of acquisition-related intangible assets A — 352 4.9 — — — — Fair value (gains) losses on investments B — — — — — 85 — Adjusted (Non-GAAP) $ 7,134 $ (1,477) (20.7) % $ (400) (5.6) % $ 16 $ (33) 5 Each of the per share amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into shares of common stock for all periods presented prior to their conversion on April 17, 2023. Net earnings per diluted common share amounts for the relevant three-month periods may not add to the year-to-date amounts due to rounding. DANAHER CORPORATION Other Non-GAAP Adjusted P&L Measures ($ in millions, except per share data) 9 -- 23 of 33 -- Year Ended December 31, 2023 Sales Cost of sales Gross profit margin Operating profit Operating profit margin Earnings from continuing operations before income taxes Income taxes Net earnings from continuing operations for calculation of diluted earnings per common share Diluted net earnings per common share from continuing operations 5 Reported (GAAP) $ 23,890 $ (9,856) 58.7 % $ 5,202 21.8 % $ 5,044 $ (823) $ 4,200 J $ 5.65 Amortization of acquisition-related intangible assets A — — — 1,491 6.2 1,491 1,491 2.00 Fair value net (gains) losses on investments B — — — — — 182 182 0.24 Impairments and other charges C — 14 0.1 77 0.3 77 77 0.10 Acquisition-related items D — 8 — 95 0.4 95 95 0.13 Litigation gains E — — — (10) — (10) (10) (0.01) Tax effect of the above adjustments G (354) (354) (0.47) Discrete tax adjustments H (47) (47) (0.06) MCPS "as if converted" I — — — — — — — 21 0.01 Rounding — — — — — — — — (0.01) Adjusted (Non-GAAP) $ 23,890 $ (9,834) 58.8 % $ 6,855 28.7 % $ 6,879 $ (1,224) $ 5,655 $ 7.58 Year Ended December 31, 2023 Sales Selling, general and administrative expenses Selling, general and administrative expenses as a % of sales Research and development expenses Research and development expenses as a % of sales Nonoperating income (expense), net (excluding interest) Interest income (expense), net Reported (GAAP) $ 23,890 $ (7,329) (30.7) % $ (1,503) (6.3) % $ (175) $ 17 Amortization of acquisition-related intangible assets A — 1,491 6.2 — — — — Fair value net (gains) losses on investments B — — — — — 182 — Impairments and other charges C — 63 0.3 — — — — Acquisition-related items D — 87 0.4 — — — — Litigation gains E — (10) — — — — — Rounding — — (0.1) — — — — Adjusted (Non-GAAP) $ 23,890 $ (5,698) (23.9) % $ (1,503) (6.3) % $ 7 $ 17 5 Each of the per share amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into shares of common stock for all periods presented prior to their conversion on April 17, 2023. Net earnings per diluted common share amounts for the relevant three-month periods may not add to the year-to-date amounts due to rounding. DANAHER CORPORATION Other Non-GAAP Adjusted P&L Measures ($ in millions, except per share data) 10 -- 24 of 33 -- Year Ended December 31, 2022 Sales Cost of sales Gross profit margin Operating profit Operating profit margin Earnings from continuing operations before income taxes Income taxes Net earnings from continuing operations for calculation of diluted earnings per common share Diluted net earnings per common share from continuing operations 5 Reported (GAAP) $ 26,643 $ (10,455) 60.8 % $ 7,536 28.3 % $ 7,146 $ (818) $ 6,242 J $ 8.47 Amortization of acquisition-related intangible assets A — — — 1,434 5.4 1,434 1,434 1.92 Fair value net (gains) losses on investments B — — — — — 271 271 0.36 Impairments and other charges C — 18 0.1 42 0.2 42 42 0.06 Loss on partial settlement of a defined benefit plan F — — — — — 10 10 0.01 Tax effect of the above adjustments G (345) (345) (0.46) Discrete tax adjustments H (500) (500) (0.67) MCPS "as if converted" I — — — — — — — 86 0.02 Rounding — — (0.1) — (0.1) — — — — Adjusted (Non-GAAP) $ 26,643 $ (10,437) 60.8 % $ 9,012 33.8 % $ 8,903 $ (1,663) $ 7,240 $ 9.71 Year Ended December 31, 2022 Sales Selling, general and administrative expenses Selling, general and administrative expenses as a % of sales Research and development expenses Research and development expenses as a % of sales Nonoperating income (expense) net (excluding interest) Interest income (expense), net Reported (GAAP) $ 26,643 $ (7,124) (26.7) % $ (1,528) (5.7) % $ (227) $ (163) Amortization of acquisition-related intangible assets A — 1,434 5.4 — — — — Fair value net (gains) losses on investments B — — — — — 271 — Impairments and other charges C — 24 0.1 — — — — Loss on partial settlement of a defined benefit plan F — — — — — 10 — Rounding — — (0.1) — — — — Adjusted (Non-GAAP) $ 26,643 $ (5,666) (21.3) % $ (1,528) (5.7) % $ 54 $ (163) 5 Each of the per share amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into shares of common stock for all periods presented. Net earnings per diluted common share amounts for the relevant three-month periods may not add to the year-to-date amounts due to rounding. DANAHER CORPORATION Other Non-GAAP Adjusted P&L Measures ($ in millions, except per share data) 11 -- 25 of 33 -- A Amortization of acquisition-related intangible assets in the following historical periods ($ in millions) (only the pretax amounts set forth below are reflected in the amortization line item above): Three-Month Period Ended Year Ended December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Pretax $ 380 $ 352 $ 1,491 $ 1,434 After-tax 317 286 1,226 1,166 B Net (gains) losses, including impairments, on the Company's equity and limited partnership investments recorded in the following historical periods ($ in millions) (only the pretax amounts set forth below are reflected in the fair value net (gains) losses on investments line above): Three-Month Period Ended Year Ended December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Pretax $ 139 $ 85 $ 182 $ 271 After-tax 98 57 130 198 C Impairment charge related to technology-based intangible assets in the Diagnostics segment recorded in the three-month period and year ended December 31, 2023 ($23 million pretax as reported in this line, $18 million after-tax) and technology-based intangible assets and other assets in the Biotechnology segment recorded in the three-month period and year ended December 31, 2023 ($12 million and $54 million pretax as reported in this line item, $8 million and $40 million after-tax, respectively). In the year ended December 31, 2022 charges incurred primarily related to impairments of accounts receivable and inventory as well as accruals for contractual obligations in Russia ($42 million pretax as reported in this line item, $39 million after-tax). D Transaction costs deemed significant, settlement of pre-acquisition share-based payment awards and fair value adjustments to inventory in each case related to the acquisition of Abcam in the three-month period and year ended December 31, 2023 ($95 million pretax as reported in this line item, $75 million after-tax). The Company deems acquisition-related transaction costs incurred in a given period to be significant (generally relating to the Company’s larger acquisitions) if it determines that such costs exceed the range of acquisition-related transaction costs typical for Danaher in a given period. E Gain related to settlement of litigation in the Life Sciences segment recorded in the three-month period and year ended December 31, 2023 ($10 million pretax as reported in this line, $8 million after-tax). F Loss on a partial settlement of a defined benefit plan as a result of the transfer of a portion of the Company’s non-U.S. pension liabilities related to one defined benefit plan to a third-party in the year ended December 31, 2022 ($10 million pretax as reported in this line item, $9 million after-tax). G This line item reflects the aggregate tax effect of all non-tax adjustments reflected in the preceding line items of the table. In addition, the footnotes above indicate the after-tax amount of each individual adjustment item. Danaher estimates the tax effect of each adjustment item by applying Danaher’s overall estimated effective tax rate to the pretax amount, unless the nature of the item and/or the tax jurisdiction in which the item has been recorded requires application of a specific tax rate or tax treatment, in which case the tax effect of such item is estimated by applying such specific tax rate or tax treatment. The MCPS dividends are not tax deductible and therefore the tax effect of the adjustments does not include any tax impact of the MCPS dividends. H Discrete tax adjustments and other tax-related adjustments for the three-month period ended December 31, 2023, include the impact of net discrete tax benefits of $71 million due principally to net deferred tax benefits resulting from changes in estimates related to prior year tax filing positions and the release of reserves for uncertain tax positions due to the expiration of statutes of limitation, net of charges related to changes in estimates associated with prior period uncertain tax positions. Discrete tax adjustments and other tax-related adjustments for the year ended December 31, 2023 include the impact of net discrete tax benefits of $47 million due principally to net discrete tax benefits from changes in estimates related to prior year tax filing positions, the release of reserves for uncertain tax positions due to the expiration of statutes of limitation and excess tax benefits from stock-based compensation, net of charges related to tax costs related to the separation of Veralto Corporation, tax costs from legal and operational actions undertaken to realign certain of its businesses and changes in estimates associated with prior period uncertain tax positions. Discrete tax adjustments for both the three-month period DANAHER CORPORATION Other Non-GAAP Adjusted P&L Measures ($ in millions, except per share data) 12 -- 26 of 33 -- and year ended December 31, 2022, include the impact of net discrete tax benefits of $459 million and $500 million, respectively, due principally to net deferred tax benefits resulting from legal and operational actions undertaken to realign certain of Danaher’s businesses, as well as excess tax benefits from stock-based compensation, the release of reserves for uncertain tax positions due to the expiration of statutes of limitation and audit settlements and changes in estimates related to prior year tax filing positions, net of changes in estimates associated with prior period uncertain tax positions. The Company anticipates excess tax benefits from stock compensation of approximately $7 million per quarter and therefore excludes benefits in excess of this amount in the calculation of adjusted diluted net earnings from continuing operations per common share. I In March 2019, the Company issued $1.65 billion in aggregate liquidation preference of 4.75% MCPS Series A. In May 2020, the Company issued $1.72 billion in aggregate liquidation preference of 5.0% MCPS Series B. Dividends on the MCPS Series A and Series B were payable on a cumulative basis at an annual rate of 4.75% and 5.0%, respectively, on the liquidation preference of $1,000 per share. Each share of MCPS Series A converted on April 15, 2022 into 6.6632 shares of Danaher’s common stock. Each share of MCPS Series B converted on April 17, 2023 into 5.0175 shares of Danaher’s common stock. For the calculation of net earnings per common share from continuing operations, the impact of the dilutive MCPS is calculated under the “if-converted” method and the related MCPS dividends are excluded. For the purposes of calculating adjusted earnings per common share from continuing operations, the Company has excluded the paid MCPS cash dividends and assumed the “if-converted” method of share dilution (the incremental shares of common stock deemed outstanding applying the “if-converted” method of calculating share dilution only with respect to any MCPS the conversion of which would be dilutive in the particular period are referred to as the “Converted Shares”) for any MCPS that were anti-dilutive for the given period. For additional information about the impact of the MCPS on the calculation of diluted EPS, see note 6 in the Average and Adjusted Average Common Stock and Common Equivalent Diluted Shares Outstanding table below. J Net earnings from continuing operations for calculation of diluted earnings per common share is summarized as follows ($ in millions): Three-Month Period Ended Year Ended December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Net earnings from continuing operations $ 1,121 $ 2,012 $ 4,221 $ 6,328 MCPS dividends — (22) (21) (106) Net earnings from continuing operations attributable to common stockholders for Basic EPS 1,121 1,990 4,200 6,222 Adjustment for MCPS dividends for dilutive MCPS — 22 — 20 Net earnings from continuing operations attributable to common stockholders after assumed conversions for Diluted EPS $ 1,121 $ 2,012 $ 4,200 $ 6,242 DANAHER CORPORATION Other Non-GAAP Adjusted P&L Measures ($ in millions, except per share data) 13 -- 27 of 33 -- Three-Month Period Ended Year Ended December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Average common stock and common equivalent shares outstanding - diluted (GAAP) 6 746.1 745.7 743.1 737.1 Converted shares 7 — — 2.5 8.6 Adjusted average common stock and common equivalent shares outstanding - diluted (non-GAAP) 746.1 745.7 745.6 745.7 6 The impact of the MCPS Series B calculated under the if-converted method was anti-dilutive for the years ended December 31, 2023 and 2022, and as such, approximately 2.5 million shares and 8.6 million shares, respectively, underlying the MCPS Series B are excluded from the calculation of diluted EPS for the periods and the related MCPS Series B dividends of $21 million and $86 million were included in the calculation of net earnings for diluted EPS for the respective periods. The impact of the MCPS Series B calculated under the if-converted method was dilutive for the three-month period ended December 31, 2022, and as such 8.6 million shares underlying the MCPS Series B were included in the calculation of diluted EPS in the period and the related MCPS Series B dividends of $22 million were excluded from the calculation of net earnings for diluted EPS for the period. The impact of the MCPS Series A calculated under the if-converted method was dilutive for the year ended December 31, 2022, and as such 3.0 million shares underlying the MCPS Series A were included in the calculation of diluted EPS in the periods and the related MCPS Series A dividends of $20 million were excluded from the calculation of net earnings for diluted EPS for the period. 7 The number of converted shares assumes the conversion of all MCPS and issuance of the underlying shares applying the “if-converted” method of accounting and using the actual conversion rates for the year ended December 31, 2023 and an average 20 trading-day trailing Volume Weighted Average Price of $266.27 as of December 31, 2022. DANAHER CORPORATION Average and Adjusted Average Common Stock and Common Equivalent Diluted Shares Outstanding (shares in millions) 14 -- 28 of 33 -- Segments Total Company Biotechnology Life Sciences Diagnostics Three-Month Period Ended December 31, 2022 Operating Profit Margins from Continuing Operations (GAAP) 28.00 % 31.20 % 20.10 % 33.40 % Fourth quarter 2023 impact from operating profit margins of businesses that have been owned for less than one year or were disposed of during such period and did not qualify as discontinued operations (0.25) — (0.75) — Fourth quarter 2023 transaction costs deemed significant, settlement of pre-acquisition share-based payment awards and fair value adjustments to inventory, in each case related to the acquisition of Abcam (1.50) — (4.90) — Fourth quarter 2023 impairment charge related to technology-based intangible assets in the Diagnostics segment and technology-based intangible assets in the Biotechnology segment (0.55) (0.70) — (0.90) Fourth quarter 2023 gain from the resolution of a litigation contingency in the Life Sciences segment 0.15 — 0.55 — Year-over-year core operating profit margin changes for the fourth quarter 2023 (defined as all year-over-year operating profit margin changes other than the changes identified in the line items above) (non-GAAP) (4.95) (6.90) (2.80) (4.30) Three-Month Period Ended December 31, 2023 Operating Profit Margins from Continuing Operations (GAAP) 20.90 % 23.60 % 12.20 % 28.20 % Segments Total Company Biotechnology Life Sciences Diagnostics Year Ended December 31, 2022 Operating Profit Margins from Continuing Operations (GAAP) 28.30 % 34.30 % 20.10 % 31.70 % Full year 2023 impact from operating profit margins of businesses that have been owned for less than one year or were disposed of during such period and did not qualify as discontinued operations (0.20) (0.10) (0.45) (0.05) Fourth quarter 2023 transaction costs deemed significant, settlement of pre-acquisition share-based payment awards and fair value adjustments to inventory, in each case related to the acquisition of Abcam (0.40) — (1.30) — Fourth quarter 2023 impairment charge related to technology-based intangible assets in the Diagnostics segment and second and fourth quarter 2023 impairment charges related to technology-based intangible assets and other assets in the Biotechnology segment (0.35) (0.75) — (0.25) Fourth quarter 2023 gain from the resolution of a litigation contingency in the Life Sciences segment 0.05 — 0.15 — Full year 2022 impairments of accounts receivable and inventory as well as accruals for contractual obligations in Russia 0.15 0.15 0.35 0.05 Year-over-year core operating profit margin changes for full year 2023 (defined as all year-over-year operating profit margin changes other than the changes identified in the line items above) (non-GAAP) (5.75) (7.00) (1.95) (6.35) Year Ended December 31, 2023 Operating Profit Margins from Continuing Operations (GAAP) 21.80 % 26.60 % 16.90 % 25.10 % Note: The Company deems acquisition-related transaction costs incurred in a given period to be significant (generally relating to the Company’s larger acquisitions) if it determines that such costs exceed the range of acquisition-related transaction costs typical for Danaher in a given period. DANAHER CORPORATION Year-Over-Year Core Operating Margin Changes from Continuing Operations 15 -- 29 of 33 -- Three-Month Period Ended Year-over-Year Change Year Ended Year-over-Year Change December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Total Cash Flows from Continuing Operations: Total cash provided by operating activities from continuing operations (GAAP) $ 1,591 $ 2,200 $ 6,490 $ 7,613 Total cash used in investing activities from continuing operations (GAAP) $ (6,017) $ (804) $ (7,048) $ (2,145) Total cash (used in) provided by financing activities from continuing operations (GAAP) $ (1,819) $ (906) $ 154 $ (2,570) Free Cash Flow from Continuing Operations: Total cash provided by operating activities from continuing operations (GAAP) $ 1,591 $ 2,200 ~(27.5) % $ 6,490 $ 7,613 ~(15.0) % Less: payments for additions to property, plant & equipment (capital expenditures) from continuing operations (GAAP) (434) (321) (1,383) (1,118) Plus: proceeds from sales of property, plant & equipment (capital disposals) from continuing operations (GAAP) 6 — 12 9 Free cash flow from continuing operations (non-GAAP) $ 1,163 $ 1,879 ~(38.0) % $ 5,119 $ 6,504 ~(21.5) % Operating Cash Flow to Net Earnings Ratio (GAAP) Total cash provided by operating activities from continuing operations (GAAP) $ 1,591 $ 2,200 $ 6,490 $ 7,613 Net earnings from continuing operations (GAAP) $ 1,121 $ 2,012 $ 4,221 $ 6,328 Operating cash flow from continuing operations to net earnings from continuing operations conversion ratio 1.42 1.09 1.54 1.20 Free Cash Flow to Net Earnings Ratio (non-GAAP) Free cash flow from continuing operations from above (non-GAAP) $ 1,163 $ 1,879 $ 5,119 $ 6,504 Net earnings from continuing operations (GAAP) $ 1,121 $ 2,012 $ 4,221 $ 6,328 Free cash flow from continuing operations to net earnings from continuing operations conversion ratio (non-GAAP) 1.04 0.93 1.21 1.03 The Company defines free cash flow as operating cash flows from continuing operations, less payments for additions to property, plant and equipment from continuing operations (“capital expenditures”) plus the proceeds from sales of plant, property and equipment from continuing operations (“capital disposals”). All amounts presented above reflect only continuing operations. DANAHER CORPORATION Cash Flow from Continuing Operations, Free Cash Flow from Continuing Operations, Operating Cash Flow from Continuing Operations to Net Earnings from Continuing Operations Ratio and Free Cash Flow from Continuing Operations to Net Earnings from Continuing Operations Conversion Ratio ($ in millions) 16 -- 30 of 33 -- Each of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies. Management believes that these measures provide useful information to investors by offering additional ways of viewing Danaher Corporation’s (“Danaher” or the “Company”) results that, when reconciled to the corresponding GAAP measure, help our investors: • with respect to the profitability-related non-GAAP measures, understand the long-term profitability trends of our business and compare our profitability to prior and future periods and to our peers; • with respect to core sales and related non-GAAP sales measures, identify underlying growth trends in our business and compare our sales performance with prior and future periods and to our peers; and • with respect to free cash flow from continuing operations and related non-GAAP cash flow measures (the “FCF Measure”), understand Danaher’s ability to generate cash without external financings, strengthen its balance sheet, invest in its business and grow its business through acquisitions and other strategic opportunities (although a limitation of free cash flow is that it does not take into account the Company’s debt service requirements and other non- discretionary expenditures, and as a result the entire free cash flow amount is not necessarily available for discretionary expenditures). We expect overall demand for the Company’s COVID-19 related products to continue moderating as the pandemic has evolved toward endemic status. We believe certain demand for the Company’s products that support COVID-19 related vaccines and therapeutics and COVID-19 testing (which includes solutions that test for COVID-19 and other respiratory illnesses simultaneously) will continue, though that demand will likely be uncertain and will vary from period to period. At the beginning of 2022, the Company believed that on a relative basis, the level of ongoing demand for products supporting COVID-19 testing would be subject to more fluctuations in demand than the level of demand for products supporting COVID-19 related vaccines and therapeutics, due in part to expected COVID-19 case levels, vaccination rates and use of therapies. However, as a result of lower vaccination rates and the spread of less severe variants of the virus, 2022 demand for the Company’s products supporting COVID-19 related vaccines and therapeutics fluctuated and declined more than anticipated at the beginning of the year. Therefore, beginning with the first quarter of 2023, we have revised the definition of “base business core sales growth” on a basis that not only excludes revenues related to COVID-19 testing but also excludes revenues from products that support COVID-19 related vaccines and therapeutics. We believe this adjusted definition of “base business core sales growth” provides more useful information to investors by facilitating period-to-period comparisons of our financial performance and identifying underlying growth trends in the Company’s business that otherwise may be obscured by fluctuations in demand for COVID-19 related products. Management uses the non-GAAP measures referenced above to measure the Company’s operating and financial performance, and uses core sales and non- GAAP measures similar to Adjusted Diluted Net Earnings Per Common Share from Continuing Operations and the FCF Measure in the Company’s executive compensation program. • The items excluded from the non-GAAP measures set forth above have been excluded for the following reasons: ◦ Amortization of Intangible Assets: We exclude the amortization of acquisition-related intangible assets because the amount and timing of such charges are significantly impacted by the timing, size, number and nature of the acquisitions we consummate. While we have a history of significant acquisition activity we do not acquire businesses on a predictable cycle, and the amount of an acquisition’s purchase price allocated to intangible assets and related amortization term are unique to each acquisition and can vary significantly from acquisition to acquisition. Exclusion of this amortization expense facilitates more consistent comparisons of operating results over time between our newly acquired and long-held businesses, and with both acquisitive and non-acquisitive peer companies. We believe however that it is important for investors to understand that such intangible assets contribute to sales generation and that intangible asset amortization related to past acquisitions will recur in future periods until such intangible assets have been fully amortized. ◦ Restructuring Charges: We exclude costs incurred pursuant to discrete restructuring plans that are fundamentally different (in terms of the size, strategic nature and planning requirements, as well as the inconsistent frequency, of such plans) from the ongoing productivity improvements that result from application of the Danaher Business System. Because these restructuring plans are incremental to the core activities that arise in the ordinary course of our business and we believe are not indicative of Danaher’s ongoing operating costs in a given period, we exclude these costs to facilitate a more consistent comparison of operating results over time. DANAHER CORPORATION Statement Regarding Non-GAAP Measures 17 -- 31 of 33 -- ◦ Other Adjustments: With respect to the other items excluded from Adjusted Diluted Net Earnings Per Common Share from Continuing Operations, we exclude these items because they are of a nature and/or size that occur with inconsistent frequency, occur for reasons that may be unrelated to Danaher's commercial performance during the period and/or we believe that such items may obscure underlying business trends and make comparisons of long-term performance difficult. For example, we excluded the first quarter 2022 charge for asset impairments, accruals for contractual obligations and similar items related to our Russia operations because, even though it is possible we could incur additional charges in the future, we do not believe these charges are indicative of Danaher’s ongoing operating costs. • With respect to adjusted average common stock and common equivalent shares outstanding, Danaher’s Mandatory Convertible Preferred Stock (“MCPS”) Series A converted into Danaher common stock on April 15, 2022 and the MCPS Series B mandatorily converted into Danaher common stock on the mandatory conversion date of April 17, 2023 (unless converted or redeemed earlier in accordance with the terms of the applicable certificate of designations). With respect to the calculation of Adjusted Diluted Net Earnings Per Common Share from Continuing Operations, we apply the “if converted” method of share dilution to the MCPS Series A and B in all applicable periods irrespective of whether such preferred shares were dilutive or anti-dilutive in the period. We believe this presentation provides useful information to investors by helping them understand the net impact on Danaher’s earnings per share-related measures irrespective of the period. • With respect to core operating profit margin changes, in addition to the explanation set forth in the bullets above relating to “restructuring charges” and “other adjustments”, we exclude the impact of businesses owned for less than one year (or disposed of during such period and not treated as discontinued operations) because the timing, size, number and nature of such transactions can vary significantly from period to period and may obscure underlying business trends and make comparisons of long-term performance difficult. • We calculate adjusted EBITDA by adding to operating profit amounts equal to depreciation and amortization and making the other adjustments reflected in the applicable tables above, which allows us to calculate and disclose such measure by segment. Given Danaher’s diversification, we believe this helps our investors compare the profitability of our individual segments to peer companies with like business lines. • With respect to core sales related measures, (1) we exclude the impact of currency translation because it is not under management’s control, is subject to volatility and can obscure underlying business trends, and (2) we exclude the effect of acquisitions and divested product lines because the timing, size, number and nature of such transactions can vary significantly from period-to-period and between us and our peers, which we believe may obscure underlying business trends and make comparisons of long-term performance difficult. • With respect to the FCF Measure, we exclude payments for additions to property, plant and equipment (net of the proceeds from capital disposals) to demonstrate the amount of operating cash flow for the period that remains after accounting for the Company’s capital expenditure requirements. The Company provides forecasted sales only on a non-GAAP basis because of the difficulty in estimating the other components of GAAP revenue, such as currency translation, acquisitions and divested product lines. Additionally, we do not reconcile forecasted adjusted operating profit margin (or components thereof) to the comparable GAAP measures because of the difficulty in estimating the other components (in addition to items identified in the prior sentence) such as investment gains and losses, impairments and separation costs, which would be reflected in any forecasted GAAP operating profit. DANAHER CORPORATION Statement Regarding Non-GAAP Measures 18 -- 32 of 33 -- 19 -- 33 of 33 --